Acquired red cell aplasia
Not for Routine Use
When screening requests for approval, the following information may be taken into account as there is some evidence for IG to be considered as an option.
Order Number: H15-ARCA
| Recommendations | IVIG is an option for patients with immunologic pure red cell aplasia (PRCA) who have failed other therapies (e.g., prednisone or cyclosporin). IVIG should be considered first-line therapy for viral PRCA associated with parvovirus B19 in immunocompromised patients. See separate entry Parvovirus B19 in solid organ transplant recipients. |
| Dose/Frequency of Administration | Up to 2 g/kg divided over 2 to 5 consecutive days for short term use. Repeat on relapse. |